## SUPPLEMENTARY INFORMATION

## Molecular design of radiocopper-labelled affibody molecules

Vladimir Tolmachev<sup>1, ©,</sup> Tove J Grönroos<sup>2, 3, 4, ®</sup>, Cheng-Bin Yim<sup>2, 5,</sup>, Javad Garousi<sup>1</sup>, Ying Yue<sup>6</sup>, Sebastian Grimm<sup>6</sup>, Johan Rajander<sup>5</sup>, Anna Perols<sup>6</sup>, Merja Haaparanta-Solin<sup>2, 7</sup>, Olof Solin<sup>2, 5, 7</sup>, Riccardo Ferdani<sup>8</sup>, Anna Orlova<sup>9</sup>, Carolyn Anderson<sup>10</sup>, Amelie Eriksson Karlström<sup>6</sup>.

<sup>©</sup> VT and TJG contributed equally

<sup>1</sup> Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;

<sup>2</sup> Turku PET Centre, University of Turku, Turku, Finland;

<sup>3</sup> MediCity Research Laboratory, University of Turku, Turku, Finland;

<sup>4</sup> Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland


<sup>5</sup> Turku PET Centre, Åbo Akademi University, Turku, Finland;
<sup>6</sup>Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden;

<sup>7</sup> Department of Chemistry, University of Turku, Turku, Finland;


<sup>8</sup> Washington University, St. Louis, MO

<sup>9</sup>Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden

<sup>10</sup> Departments of Medicine, Radiology, Bioengineering and Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15203, USA



**Figure S1.** CD studies of CB–TE2A–GEEE–ZHER2:342. CD spectra recorded at 20 °C before and after variable temperature measurements (left) and the thermal melting curve recorded at 221 nm (right).



**Figure S2.** CD studies of CB–TE2A–G–ZHER2:342. CD spectra recorded at 20°C before and after variable temperature measurements (left) and the thermal melting curve recorded at 221 nm (right)

**Table S1.** Stability of <sup>64</sup>Cu-CB-TE2A-GEEE-ZHER2:342 and <sup>64</sup>Cu-CB-TE2A-G-ZHER2:342 under 1-h challenge with 500-fold excess of EDTA.

	Peptide-associated radioactivity (%)	
	<sup>64</sup> Cu-CB-TE2A-G-	<sup>64</sup> Cu-CB-TE2A-GEEE-
	ZHER2:342	ZHER2:342
EDTA solution	$99.1 \pm 0.0$	$99.8\pm0.3$
PBS (control)	99.3 ± 0.2	99.7 ± 0.1